Quadria Capital Eyes Med-Tech, Outsourcing After Nephroplus Success; $1.07B Fund Ready

• Quadria Capital saw strong returns (nearly 2x) from Nephroplus's successful listing, remaining its largest shareholder with no immediate exit plans.
• The firm closed its third fund at $1.07 billion, 60% larger than its predecessor, to be deployed across five core investment themes.
• Key investment themes include localisation, outsourcing (India/Vietnam), consumer healthcare, digital healthcare, and roll-up strategies in fragmented segments.
• Quadria maintains focus on single speciality, speciality pharma, CRDMOs, and sees "China plus one" shift to India/SEA in 3-5 years.
• Future opportunities include outsourcing-led businesses, preventive healthcare, and Med-Tech, which Quadria identifies as the next major focus area for indigenisation.

Why It Matters: Quadria Capital leverages Nephroplus success, deploys $1.07B fund into Med-Tech, outsourcing, and healthcare.